title: Diabetes: making sense of the rosiglitazone controversy.
abstract: Whether thiazolidinediones should be used to treat patients with type 2 diabetes mellitus is controversial, as studies on the cardiovascular effects of these drugs have produced conflicting results. A trial in which rosiglitazone and glipizide were compared supports earlier findings that rosiglitazone does not have an adverse effect on the progression of coronary atherosclerosis.
authors.affiliation: Clinical Trials Unit, Mount Sinai Cardiovascular Institute, One Gustave L. Levy Place, Box 1074, New York, NY 10029, USA.
authors.forename: Michael E
authors.initials: ME
authors.lastname: Farkouh
authors.forename: Valentin
authors.initials: V
authors.lastname: Fuster
mesh_terms: D002318:Cardiovascular Diseases / Q000139:chemically induced*; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D019317:Evidence-Based Medicine; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects*; D018579:Patient Selection; D018570:Risk Assessment; D012307:Risk Factors; D000077154:Rosiglitazone; D045162:Thiazolidinediones / Q000009:adverse effects*; D016896:Treatment Outcome
chemical_list: D007004:Hypoglycemic Agents; D045162:Thiazolidinediones; D000077154:Rosiglitazone